BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21220328)

  • 1. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
    Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
    Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
    PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
    BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
    McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
    Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
    Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP
    Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
    Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
    Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
    Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
    J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMI1 sustains human glioblastoma multiforme stem cell renewal.
    Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
    J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of genome-wide genechip for screening and identifying genes related to CD133(+)CD200(+) colorectal cancer stem cells].
    Zhang S; Li L; Huang Z; Xin X; Xiao B
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1787-91. PubMed ID: 24369246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
    Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
    Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
    Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
    Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.